MV-140
PreclinicalSmall molecule
MV-140 is one of 10 small molecule programs targeting Recurrent urinary tract infections. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Recurrent Urinary Tract Infections
#DrugCompanyPhaseTrials
1Monurol
MMeitheal
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Merrem
BB. Braun Medical Inc.
Approved
Vagifem
Novo NordiskPhase 3
ESTRING
UUniversity of California, San Francisco
Phase 3
Cipro
BayerPreclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Amikin
IInsmed Incorporated
Preclinical
MV-140
UUnidade Local de Saúde Santa Maria
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MV-140. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details